Elevated Microsatellite Alterations at Selected Tetra-nucleotide (EMAST) in Non-small Cell Lung Cancers--a Potential Determinant of Susceptibility to Multiple Malignancies

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2013 Feb 16

PMID 23412080

Citations 10

Authors

Hiromasa Arai

Koji Okudela

Hisashi Oshiro

Noriko Komitsu

Hideaki Mitsui

Teppei Nishii

Masahiro Tsuboi

Akinori Nozawa

Yasuharu Noishiki

Kenichi Ohashi

Kenji Inui

Munetaka Masuda

Affiliations

Soon will be listed here.

Abstract

The present study evaluated the potential clinicopathologic significance of elevated microsatellite alteration at selected tetra-nucleotide (EMAST) in non-small cell lung cancer (NSCLC). Sixty-five NSCLCs (19 squamous cell carcinomas, 39 adenocarcinomas, one adenosquamous cell carcinoma, and 6 large cell carcinomas) were examined for EMAST in the ten selected tetra-nucleotide markers. Traditional microsatellite instability (MSI) in the five mono- or di-nucleotide markers of the Bethesda panel was also examined, and compared with EMAST. The incidence of EMAST was higher than that of traditional MSI, as 64.6% (42/65) and 12.3% (8/65) tumors respectively exhibited EMAST and traditional MSI in at least one marker. EMAST and traditional MSI appear to occur independently, as no significant association in their incidence was found (Fisher's exact test, P = 0.146). Subjects who exhibited EMAST in two or more markers had a significantly higher incidence of history of other malignant neoplasms (42.9% [9/21]), compared to those with less than two markers (16.3% [7/43] (Chi-square test, P = 0.021)). Taken together, impairment of molecular machinery for maintaining stable replication of the tetra-nucleotide-repeating regions, which would differ from machinery for mono- or di-nucleotide-repeating regions, may elevate susceptibility to NSCLCs and certain neoplastic diseases. Elucidation of the potential molecular mechanism of EMAST is expected to lead to a discovery of a novel genetic background determining susceptibility to NSCLC and other multiple neoplasms. This is the first report describing a clinicopathologic significance of EMAST in NSCLC.

Citing Articles

Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) in Penile Squamous Cell Carcinoma-No Evidence for a Role in Carcinogenesis.

Fiegl A, Wendler O, Giedl J, Gaisa N, Richter G, Campean V Curr Oncol. 2024; 31(10):5752-5761.

PMID: 39451731 PMC: 11505989. DOI: 10.3390/curroncol31100427.

EMAST Type of Microsatellite Instability-A Distinct Entity or Blurred Overlap between Stable and MSI Tumors.

Derfi K, Salar A, Cacev T, Kapitanovic S Genes (Basel). 2023; 14(7).

PMID: 37510378 PMC: 10380056. DOI: 10.3390/genes14071474.

The Clinicopathological Features and Genetic Mutations in Gastric Cancer Patients According to EMAST and MSI Status.

Fang W, Chen M, Huang K, Chang S, Lin C, Chao Y Cancers (Basel). 2020; 12(3).

PMID: 32120855 PMC: 7139949. DOI: 10.3390/cancers12030551.

Combined Microsatellite Instability and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) Might Be a More Promising Immune Biomarker in Colorectal Cancer.

Chen M, Chang S, Lin P, Yang S, Lin C, Lan Y Oncologist. 2019; 24(12):1534-1542.

PMID: 31292272 PMC: 6975953. DOI: 10.1634/theoncologist.2019-0171.

A new method for discovering EMAST sequences in animal models of cancer.

Bhaskaran N, Luu J, Kelley S, Khan M, Mamindla P, McGuire K Sci Rep. 2018; 8(1):13764.

PMID: 30214002 PMC: 6137214. DOI: 10.1038/s41598-018-32057-2.

References

Ahrendt S, Decker P, Doffek K, Wang B, Xu L, Demeure M . Microsatellite instability at selected tetranucleotide repeats is associated with p53 mutations in non-small cell lung cancer. Cancer Res. 2000; 60(9):2488-91. View

Lothe R . Microsatellite instability in human solid tumors. Mol Med Today. 1997; 3(2):61-8. DOI: 10.1016/S1357-4310(96)10055-1. View

Sekido Y, Fong K, Minna J . Molecular genetics of lung cancer. Annu Rev Med. 2002; 54:73-87. DOI: 10.1146/annurev.med.54.101601.152202. View

Woo T, Okudela K, Yazawa T, Wada N, Ogawa N, Ishiwa N . Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas. Lung Cancer. 2009; 65(3):355-62. DOI: 10.1016/j.lungcan.2008.11.020. View

Ou S, Zell J, Ziogas A, Anton-Culver H . Prognostic factors for survival of stage I nonsmall cell lung cancer patients : a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003. Cancer. 2007; 110(7):1532-41. DOI: 10.1002/cncr.22938. View

Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M . A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol. 2008; 3(1):46-52. DOI: 10.1097/JTO.0b013e31815e8577. View

Lengauer C, Kinzler K, Vogelstein B . Genetic instabilities in human cancers. Nature. 1999; 396(6712):643-9. DOI: 10.1038/25292. View

Peltomaki P, Lothe R, Aaltonen L, Pylkkanen L, Nystrom-Lahti M, Seruca R . Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome. Cancer Res. 1993; 53(24):5853-5. View

Cheng K, Loeb L . Genomic instability and tumor progression: mechanistic considerations. Adv Cancer Res. 1993; 60:121-56. DOI: 10.1016/s0065-230x(08)60824-6. View

10.

Rodriguez-Bigas M, Boland C, Hamilton S, Henson D, Jass J, Khan P . A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst. 1997; 89(23):1758-62. DOI: 10.1093/jnci/89.23.1758. View

11.

Spira A, Ettinger D . Multidisciplinary management of lung cancer. N Engl J Med. 2004; 350(4):379-92. DOI: 10.1056/NEJMra035536. View

12.

Fong K, Zimmerman P, Smith P . Microsatellite instability and other molecular abnormalities in non-small cell lung cancer. Cancer Res. 1995; 55(1):28-30. View

13.

Yang P, Allen M, Aubry M, Wampfler J, Marks R, Edell E . Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 2005; 128(1):452-62. DOI: 10.1378/chest.128.1.452. View

14.

Mao L, Lee D, Tockman M, Erozan Y, Askin F, Sidransky D . Microsatellite alterations as clonal markers for the detection of human cancer. Proc Natl Acad Sci U S A. 1994; 91(21):9871-5. PMC: 44919. DOI: 10.1073/pnas.91.21.9871. View

15.

Burger M, Denzinger S, Hammerschmied C, Tannapfel A, Obermann E, Wieland W . Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer. J Mol Med (Berl). 2006; 84(10):833-41. DOI: 10.1007/s00109-006-0074-0. View

16.

Danaee H, Nelson H, Karagas M, Schned A, Ashok T, Hirao T . Microsatellite instability at tetranucleotide repeats in skin and bladder cancer. Oncogene. 2002; 21(32):4894-9. DOI: 10.1038/sj.onc.1205619. View

17.

Schlegel J, Bocker T, Zirngibl H, Hofstadter F, Ruschoff J . Detection of microsatellite instability in human colorectal carcinomas using a non-radioactive PCR-based screening technique. Virchows Arch. 1995; 426(3):223-7. DOI: 10.1007/BF00191358. View

18.

Pylkkanen L, Karjalainen A, Anttila S, Vainio H, Husgafvel-Pursiainen K . No evidence of microsatellite instability but frequent loss of heterozygosity in primary resected lung cancer. Environ Mol Mutagen. 1997; 30(2):217-23. DOI: 10.1002/(sici)1098-2280(1997)30:2<217::aid-em14>3.0.co;2-g. View

19.

Chang J, Chen Y, Chen C, Chen J, Chen S, Wang Y . Correlation of genetic instability with mismatch repair protein expression and p53 mutations in non-small cell lung cancer. Clin Cancer Res. 2000; 6(5):1639-46. View

20.

Zhou X, Kemp B, Khuri F, Liu D, Lee J, Wu W . Prognostic implication of microsatellite alteration profiles in early-stage non-small cell lung cancer. Clin Cancer Res. 2000; 6(2):559-65. View